Ongoing Lung Decline With Age Intensified Response
NCT07676435
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This Phase II, randomized, double-blind, placebo-controlled pilot study will evaluate the effects of fisetin, a senolytic flavonoid compound, on lung function and biomarkers of cellular senescence in older adults aged 60 years and older. Participants will include individuals with a history of at least 10 pack-years of smoking as well as age-matched never-smokers. Forty participants will be randomized to receive either fisetin or placebo using a short-course "hit-and-run" dosing strategy (approximately 20 mg/kg/day orally for 2 consecutive days on Days 1-2 and Days 8-9).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Age-Related Lung Function Decline
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 60 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Cedars-Sinai Medical Center
- Last updated on ClinicalTrials.gov
- October 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Cedars-Sinai Medical Center · Los Angeles, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.